Esperion Therapeutics Inc.
ESPR
Market Cap$490.7M
Close$
$11.14
371.9% upside
Current Fair Value
371.9% upsideUndervalued by 371.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $490.70 Million |
|---|---|
| Enterprise Value | $812.96 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.66 |
| Beta | 1.89 |
| Outstanding Shares | 189,460,293 |
| Avg 30 Day Volume | 7,930,403 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.67 |
|---|---|
| PEG | 2.85 |
| Price to Sales | 2.36 |
| Price to Book Ratio | -1.18 |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -23.44 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.68 |
| Debt to Equity | -1.87 |
Revenue Sources
No data
ESG Score
No data
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben